Skip to main content

Market Overview

UBS Downgrades Novartis To Neutral, Sees 'No Meaningful Earnings Growth Expected Before '18'

Share:

Concerns loom over the prospects of Novartis AG (ADR) (NYSE: NVS), with lack of visibility into Alcon and Entresto. UBS’ Alexandra Hauber downgraded the rating for the company from Buy to Neutral, while reducing the price target from CHF100 to CHF72.

Analyst Alexandra Hauber pointed out that Novartis' earnings momentum had been negative since the 2Q15 results. While Alcon prospects have deteriorated, Entresto’s disappointing US uptake has eroded expectations for the blockbuster candidate. “For both drivers (Alcon & Entresto), investors have struggled to predict where & when expectations will bottom,” Hauber wrote.

Take On Entresto

It has been difficult to identify the problem with Entresto’s value proposition, due to which it has been tough to “determine whether there is a potential inflection point,” the analyst commented.

The UBS report noted, “Our in¬depth review of the ongoing US clinical debate leaves us fairly confident Entresto can still turn into the $5bn blockbuster predicted by Novartis, though significant acceleration of script trends may not materialise before mid¬2017.”

The Entresto sales forecast for 2020 has been slashed from $8.3bn to $4.6bn, while the estimates Sales & Marketing spend in 2016 and 2017 have been raised. The Core EPS estimates for 2016-20¬20 have been reduced by 7¬17 percent. There is unlikely to be any meaningful earnings growth before 2018, Hauber said.

Latest Ratings for NVS

DateFirmActionFromTo
Dec 2021Exane BNP ParibasDowngradesOutperformNeutral
Dec 2021Bryan GarnierDowngradesBuyNeutral
Sep 2021Deutsche BankDowngradesHoldSell

View More Analyst Ratings for NVS

View the Latest Analyst Ratings

 

Related Articles (NVS)

View Comments and Join the Discussion!

Posted-In: Alexandra Hauber UBSAnalyst Color Downgrades Price Target Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com